Amgen's Kyprolis improves overall survival in blood cancer patients
December 11, 2017 at 16:26 PM EST
Dec 11 (Reuters) - Amgen Inc said on Monday new data from a late-stage trial testing Kyprolis in combination with two other drugs showed improved overall survival rate in patients with blood cancer.